



US005411952A

United States Patent [19]

Kaswan

[11] Patent Number: **5,411,952**
[45] Date of Patent: * May 2, 1995

[54] OCULAR CYCLOSPORINE COMPOSITION

[75] Inventor: **Renee Kaswan**, Athens, Ga.

[73] Assignee: **University of Georgia Research Foundation, Inc.**, Atlanta, Ga.

[*] Notice: The portion of the term of this patent subsequent to Jun. 13, 2006 has been disclaimed.

[21] Appl. No.: **474,683**

[22] Filed: **Feb. 6, 1990**

Related U.S. Application Data

[63] Continuation of Ser. No. 187,823, Apr. 29, 1988, abandoned, which is a continuation-in-part of Ser. No. 092,466, Sep. 3, 1987, Pat. No. 4,839,342, and Ser. No. 117,218, Nov. 4, 1987, abandoned.

[51] Int. Cl.⁶ **A61K 37/02**

[52] U.S. Cl. **514/11; 514/9;**
514/912; 514/914; 530/317; 530/321; 424/427;
424/485

[58] Field of Search 514/11, 9, 912, 914;
530/317, 321; 424/427, 485

[56] References Cited**U.S. PATENT DOCUMENTS**

4,108,985	8/1978	Ruegger et al.	514/11
4,117,118	9/1978	Harri et al.	514/11
4,210,581	7/1980	Ruegger et al.	530/321
4,215,199	7/1980	Harri et al.	435/71
4,220,641	9/1980	Traber et al.	514/11
4,288,431	9/1981	Traber et al.	514/11
4,289,851	9/1981	Traber et al.	514/11
4,384,996	5/1983	Bollinger et al.	530/321
4,388,307	6/1983	Cavanak	514/11
4,396,542	8/1983	Wenger	530/321
4,554,351	11/1985	Wenger	544/177
4,639,434	11/1987	Wenger et al.	530/321
4,649,047	3/1987	Kaswan	424/78
4,681,754	7/1987	Siegl	424/10
4,703,033	10/1987	Seebach	514/11
4,745,100	5/1988	Gilbard et al.	514/912
4,923,699	5/1990	Kaufman	424/427
4,963,367	10/1990	Ecanow	424/485

FOREIGN PATENT DOCUMENTS

0019197	8/1970	Australia	424/78
61-249918	11/1986	Japan	.
8301252	4/1983	WIPO	424/177
8404680	12/1984	WIPO	514/912

OTHER PUBLICATIONS

Hunter et al, *Clin. Exp. Immunol.*, vol. 45, pp. 173-177, (1981).

Abelson, et al. *Amer. J. Ophthal.* 95, 500-505 (1983). Abiose, et al. *Annals of Ophthal.* 15(8), 744-747, (1983). Allansmith *Clinical Ophthalmology*, Chapter 9, vol. 4 pp 1-8 (Harper & Row 1986).

BenEzra, et al., *Amer. J. Ophthal.* 101, 278-282 (1986). Grayson, *Diseases of the Cornea* pp. 334-367 (C. V. Mosby Co. 1983).

F. Hoffman and M. Wiederholt, *Klin. Mbl. Augenheilk.* 198, 92-95 (1985). (with translation).

Lemp, *Clinical Ophthalmology* vol. 4, pp. 1-10, Duane and Jaeger, editors (Harper & Row 1986).

Williams, et al., *Transplantation* 39(3), 242-244 (1985).

Williams, et al., *British J. Ophthal.* 71, 239-242 (1987).

(List continued on next page.)

Primary Examiner—Jill Warden

Assistant Examiner—T. D. Wessendorf

Attorney, Agent, or Firm—Kilpatrick & Cody

[57] ABSTRACT

Cyclosporine compositions for topical ophthalmic use for treatment of immune disorders, to enhance or restore tear production, and to enhance or effect normal healing of the surface of the eye, containing cyclosporine dissolved in corn oil. The composition may further include antioxidants, lubricants, antibiotics, antifungals, antivirals, pilocarpine, vasoconstrictors, surfactants, wetting agents, anti-inflammatory agents (i.e. corticosteroids), preservatives, mucolytic agents (i.e. bromhexine, acetylcysteine), as well as other compounds.

The preferred composition is 2% cyclosporine, 1 mole % alpha tocopherol and 0.005% methyl paraben in corn oil.

12 Claims, 2 Drawing Sheets